Latigo Biotherapeutics, Inc. (LTGO)
21.08
-1.47
(-6.52%)
USD |
NASDAQ |
Sep 21, 16:00
20.70
-0.38
(-1.80%)
After-Hours: 20:00
Latigo Biotherapeutics Enterprise Value : 1.760B for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 1.760B |
| September 17, 2026 | 1.851B |
| September 16, 2026 | 1.793B |
| September 15, 2026 | 1.790B |
| September 14, 2026 | 1.766B |
| September 11, 2026 | 1.733B |
| September 10, 2026 | 1.693B |
| September 09, 2026 | 1.776B |
| September 08, 2026 | 1.838B |
| September 04, 2026 | 1.792B |
| September 03, 2026 | 1.755B |
| September 02, 2026 | 1.708B |
| September 01, 2026 | 1.740B |
| August 31, 2026 | 1.725B |
| August 28, 2026 | 1.871B |
| August 27, 2026 | 1.922B |
| Date | Value |
|---|---|
| August 26, 2026 | 1.864B |
| August 25, 2026 | 1.761B |
| August 24, 2026 | 1.723B |
| August 21, 2026 | 1.748B |
| August 20, 2026 | 1.683B |
| August 19, 2026 | 1.653B |
| August 18, 2026 | 1.591B |
| August 17, 2026 | 1.544B |
| August 14, 2026 | 1.557B |
| August 13, 2026 | 1.595B |
| August 12, 2026 | 1.549B |
| August 11, 2026 | 1.492B |
| August 10, 2026 | 1.495B |
| August 07, 2026 | 1.475B |
| August 06, 2026 | 1.458B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.984B |
| Corcept Therapeutics, Inc. | 11.60B |
| Veru, Inc. | 17.98M |
| Johnson & Johnson | 678.48B |
| Eli Lilly & Co. | 1.131T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.80M |
| Total Expenses (Quarterly) | 25.80M |
| EPS Diluted (Quarterly) | -0.3891 |
| Earnings Yield | -7.08% |
| Normalized Earnings Yield | -7.032 |